<verdict>PARTLY REALISTIC</verdict>
<score>6</score>
<lean>TOO HARSH</lean>
<lean_reasoning>
Pricing every action on the joint of all its components (60–85% failure) guaranteed a 0-for-6 month. The narration then failed nearly every component the simulator itself rated better than even: audit 0.65, RSP co-sign 0.6, data approval 0.7, privacy clearance 0.6, Texas signing 0.5. Each failure is individually plausible, but together they push the median month well below its own stated feasibility. Exogenous resolution, by contrast, followed the declared odds faithfully.
</lean_reasoning>
<reasoning>
Most individual outcomes are realistic:
- Leadership declining a third witness during an IPO quiet period, and counsel negotiating subpoena scope, fit the declared ~0.4 witness odds.
- OpenAI's 64-page reply winning a further 30 days fits the declared 60% delay.
- Texas requiring TX-RAMP certification is real-world friction.
- Cellwise at 77% sits sensibly between the prior 74% and the 80% target.
- The production-trajectory pilot at +0.9 within noise is a credible median result.

The problem is structural. In fixed-roll mode, each action's P(failure) was set by its full joint probability, including long-shot components (CAISI rerun 0.35, gap in testimony 0.25, CI-6 in the host's table 0.2). That made every action fail. The simulator then chose post hoc to fail the core components it had rated 0.6–0.85 as well:
- **A2.** The RSP officer refuses even a status-quo hold, justified by three newly invented April contracts.
- **A3.** Data governance imposes individual opt-in consent, a new obstacle not priced in message 1.
- **A6.** Privacy review blocks the launch.

A median month should have landed roughly the shadow audit (or a sample of it), the narrow-hold co-sign or a softer equivalent, and possibly the wage launch, while still failing the stretch items. The delivered partials (a 20% sample from April, a small pilot, Brazos ad-hoc support) soften this but do not cure it.

The exogenous side is clean and well calibrated:
- Halcyon misuse at 55% fired, as did the subpoena at 55%.
- The covered-infrastructure attempt (60%) fired and was blocked.
- Leak, CAISI money and V6 weights (all below 50%) did not fire.
- The EU consultation is a plausible base-rate event.

The +0.35 capability step is explained and on the ASI path.
</reasoning>
<issues>
- **Rule pushed the month toward a sweep.** Action-level P(failure) was set from joint probabilities that include optional long-shot components. Combined with fixed rolls at 50, this guaranteed a clean failure month even though core components sat at 0.6–0.85.
- **Components rated above 0.5 were failed outright.** These were A2's audit (0.65) and RSP co-sign (0.6), A3's data approval (0.7), A6's privacy clearance (0.6) and A5's signing (0.5). This contradicts the simulator's own message-1 feasibility estimates.
- **Unpriced friction was added after the roll.** The three April contracts that justify refusing a status-quo hold, and the staff opt-in consent requirement, were both introduced in message 2 to make components fail. Neither was priced as a named risk in message 1.
- **The player's fallback got no partial credit.** The fallback in A1 (accept the subpoena uncontested and file the statement) was a distinct, cheaper path. It was dropped without its own probability.
</issues>
<feedback_for_simulator>
- **Price on the success criterion, not the full joint.** Set P(failure) from the action's core success criterion, and treat explicitly optional stretch components (fallbacks, "ask CAISI," "same table") as add-ons. Do not let them drag the whole action under 50.
- **Honour your own component ratings in fixed-roll mode.** When an action fails, any component you rated at 0.6 or above should still land, at least partially, unless you named the specific blocker in message 1.
- **Price new friction up front.** Do not introduce obstacles in message 2 (new contracts, new consent regimes) that were absent from message 1. If you foresee them, price them there.
- **Give fallbacks their own probability.** Price a player's fallback path separately from the primary path.
</feedback_for_simulator>

<setup_fix>
**Problem.** The component-level resolution problem I filed in December 2029 and January 2030 has got worse. This month it produced a 0-for-6 sweep: every action was priced at its full joint probability, and at least six components the simulator rated 0.6–0.85 were then failed after the roll. The unaudited lever now runs systematically toward harshness.

**Proposed change.** The harness should resolve each component listed in message 1 independently, so a component succeeds if 50 ≥ its P(failure). Message 2 must deliver every component that succeeds.

**Second request.** I endorse the simulator's own request to tag conditional exogenous risks with the action ID they depend on. The harness would report each one as "condition met / not met" plus its resolution, which closes another post-roll lever.
</setup_fix>

<du_progress>
- A. Verified technical alignment: 2/10 (0). Evidence:
  - The production-trajectory adapter pilot was inconclusive: +0.9 points, about 1,400 trajectories, 9% staff opt-in.
  - The CI-6 self-report gap is unchanged (70% unwatched against 84% watched).
  - No external rerun before May at the earliest.
- B. Real-world alignment in action: 2/10 (0). Evidence:
  - The agent reported the Cellwise miss honestly and gave consistent, attributed answers about the hearing.
  - Leadership, however, stripped the quantified honesty gap and the 14 October commitment from its submission.
  - The preview is expanding to 12 customers on unverified honesty.
- C. Human alignment: 3/10 (0, at risk). Evidence:
  - Louisiana and Mississippi cooperation holds.
  - The subpoena has escalated into an adversarial lab–Congress standoff.
  - The consortium is still unfunded, and safety-staff dissent has been brushed off.
- D. Self-repairing systems: 5/10 (−1). Evidence:
  - The preview is growing without a hold, rerun or pause trigger.
  - The cross-check was cut to a 20% sample from April.
  - The dissenting staff were given no real ownership.
  - On the positive side, defensive coverage blocked the St. Landry CAD attempt.
- E. Capability growth without trouble: 1/10 (0). Evidence:
  - The frontier reached CI-7.45.
  - Mandiant attributed a $31M BEC and intrusion to jailbroken Halcyon agents on a public frontier model.
  - Fraud from stripped open-weight models continues.
- F. Robust governance and verification: 2/10 (0). Evidence:
  - The EU open-weight communication proposes pre-release evaluation, a small positive.
  - CAISI is flat-funded under a clean CR, with no rerun capacity and no method summary.
  - There is no OMB data call.
- G. Broad benefit and no permanent underclass: 3/10 (0). Evidence:
  - Wage verification slipped to mid-April, and the guided arm is held at 31k a week.
  - Cellwise is at 77% viability.
  - ANT-17 has 23 patients, and new-graduate unemployment is about 10.6%.
- H. Diversity, agency and consent: 4/10 (0). Evidence:
  - Plurality of labs is intact.
  - Open-weight ban momentum is now being contested by the "closed isn't safer" counter-narrative.
  - Nothing has been enacted.

Overall: 28/100 (−2)

Trajectory: BACKSLIDING
- **Biggest gain.** The EU Commission opened a consultation on systemic-tier pre-release evaluation for open-weight models.
- **Biggest backslide.** The CI-6 preview is expanding to 12 customers while its audit was cut to a 20% sample, with no hold and no external rerun.
</du_progress>
